Short answer
Benitec Biopharma Inc. (BNTC) filed an 8-K current report with the SEC on October 28, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Positive interim Phase 1b/2a results for high-dose BB-301, a potential clinical validation milestone.
Benitec Biopharma Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Positive interim Phase 1b/2a results for high-dose BB-301, a potential clinical validation milestone
- Continued durable improvements for low-dose BB-301, supporting ongoing therapeutic activity
- Results may influence BB-301’s development path and investor expectations
Item EX-99.1 · Exhibit EX-99.1
- Interim Phase 1b/2a data support BB-301 efficacy, with 100% response across six low-dose and three high-dose patients
- High dose outperformed low dose at Month 3 for throat emptying, 100% vs 67%, and swallowing capacity, 67% vs 17%
- All Cohort 1 and Cohort 2 patients improved total SSQ scores at Month 3
- No serious adverse events reported among treated patients to date
- Pivotal BB-301 study targeted for mid-2027, creating a key upcoming development catalyst
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Benitec Biopharma Inc. 8-K filings
Get the next BNTC 8-K as it lands
Follow BNTC for push alerts, or ask the research agent what this filing means.